Genome-wide CRISPR screening uncovers potential targets and mechanisms of vincristine resistance in DLBCL.
Humans
Vincristine
/ pharmacology
Cyclophosphamide
/ therapeutic use
Rituximab
/ therapeutic use
Clustered Regularly Interspaced Short Palindromic Repeats
Doxorubicin
/ therapeutic use
Prednisone
/ therapeutic use
Lymphoma, Large B-Cell, Diffuse
/ drug therapy
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Treatment Outcome
Ubiquitin Thiolesterase
Kinesins
CRISPR
R-CHOP
diffuse large B-cell lymphoma
p53
resistance
vincristine
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
22
05
2023
received:
19
05
2023
accepted:
23
05
2023
medline:
18
8
2023
pubmed:
1
6
2023
entrez:
1
6
2023
Statut:
ppublish
Résumé
In this issue, Rovsing et al. employ unbiased genome-wide CRISPR screening and functional cellular assays to investigate the cellular response to vincristine, an important component of the front-line DLBCL treatment R-CHOP. Their findings reveal intriguing targets and mechanisms that hold promise for enhancing DLBCL treatment and provide a foundation for the development of future drug regimens. This research prompts further exploration of the translational potential to advance more effective and individualized approaches in the clinical management of DLBCL. Commentary on: Rovsing et al. Resistance to vincristine in DLBCL by disruption of p53-induced cell cycle arrest and apoptosis mediated by KIF18B and USP28. Br J Haematol 2023;202:825-839.
Substances chimiques
Vincristine
5J49Q6B70F
Cyclophosphamide
8N3DW7272P
Rituximab
4F4X42SYQ6
Doxorubicin
80168379AG
Prednisone
VB0R961HZT
USP28 protein, human
0
Ubiquitin Thiolesterase
EC 3.4.19.12
KIF18B protein, human
EC 3.6.1.-
Kinesins
EC 3.6.4.4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
720-721Informations de copyright
© 2023 British Society for Haematology and John Wiley & Sons Ltd.
Références
He MY, Kridel R. Treatment resistance in diffuse large B-cell lymphoma. Leukemia. 2021;35:2151-65.
Palmer AC, Chidley C, Sorger PK. A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity. Elife. 2019;8:e50036.
Thomsen EA, Rovsing AB, Anderson MV, Due H, Huang J, Luo Y, et al. Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma. Mol Oncol. 2020;14:1978-97.
Due H, Schönherz AA, Ryø L, Primo MN, Jespersen DS, Thomsen EA, et al. MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma. Blood Adv. 2019;3:1185-96.
Lim SK, Peng CC, Low S, Vijay V, Budiman A, Phang BH, et al. Sustained activation of non-canonical NF-κB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL. Leukemia. 2023;37:441-52.
Utsu Y, Takaishi K, Inagaki S, Arai H, Yuasa H, Masuda S, et al. Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma. Ann Hematol. 2016;95:41-7.
Tong KI, Yoon S, Isaev K, Bakhtiari M, Lackraj T, He MY, et al. Combined EZH2 inhibition and IKAROS degradation leads to enhanced antitumor activity in diffuse large B-cell lymphoma. Clin Cancer Res. 2021;27:5401-14.
Dufva O, Koski J, Maliniemi P, Ianevski A, Klievink J, Leitner J, et al. Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood. 2020;135:597-609.
Rovsing AB, Thomsen EA, Nielsen I, Skov TW, Luo Y, Dybkaer K, et al. Resistance to vincristine in DLBCL by disruption of p53-induced cell cycle arrest and apoptosis mediated by KIF18B and USP28. Br J Haematol. 2023;00:1-15.
Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386:351-63.